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Specific Growth Inhibition of Primitive Hematopoietic Progenitor Cells Mediated Through Monoclonal Antibody Binding to Major Histocompatibility Class I1 Molecules
By H.T. Greinix, R. Storb, and S.H. Bartelmez
In a previous study using a canine model, we reported that a certain anti-class II monoclonal antibody (MoAb H81.9), which recognizes an epitope formed by the Q and fl subunits of HLA-DR, prevented long-term engraftment of autologous marrow cells if administered intravenously during the first 4 days after 9.2 Gy of total body irradiation. Another MoAb (BlF6). reactive with only the @ subunit of HLA-DR and -DP, had no adverse effect on engraftment, although both MoAbs detect antigens on hematopoietic long-term repopulating cells as determined from complement-mediated lysis experiments. In the present study, continuous exposure of unfractionated human marrow to MoAb H81.9 specifically inhibited the growth of primitive progenitor cells that require multiple hematopoietic growth factors for proliferation (high prolifer-HE CURRENT general model of hematopoiesis as-T sumes that differentiated blood cells arise from a small number of pluripotent hematopoietic stem cells capable of both self-renewal and differentiation.'J Increasing maturation of the progenitor cells results in a diminishing proliferative and differentiative capacity that eventually culminates in a restriction to a particular cell lineage. Studies from this laboratory and others have shown that long-term hematopoietic repopulating cells (LTRC) in dogs and nonhuman primates express major histocompatibility complex (MHC) class I1 antigen^.^-^ Committed hematopoietic progenitor cells assayed as colony-forming units granulocyte-macrophage (CFU-GM), CFU-granulocyte-erythroid-monocyte-macrophage (CFU-GEMM), and burst-forming units-erythroid (BFU-e) are also known to express HLA-DR and -DP Further maturation in the granulocyte series results in the loss of cell surface expression of class I1 antigens while functionally mature monocytes and macrophages retain class I1 expression. ' In a previous study using a canine model, we reported that a certain anti-class I1 monoclonal antibody (MoAb) prevented long-term engraftment of autologous marrow cells if the MoAb was administered intravenously during These findings are consistent with the possibility that MoAb H81.9 modifies a primary signal pathway between LTRC and accessory or stromal cells required for maintenance or growth of repopulating cells either directly or indirectly through secondary mediators. Thus, either inhibition of growth of primitive progenitor cells or, conversely, a potent differentiation stimulus resulting in a severely reduced proliferative potential, could be the basis for the in vivo observation. To further elucidate the mechanisms involved, in vitro studies were undertaken to test the effects of MoAbs on the growth of different classes of progenitor cells using clonal assays, purified recombinant hematopoietic growth factors, and both unfractionated and enriched progenitor cell populations. Because human hematopoietic progenitor cells are better characterized than canine marrow progenitors'0-'2 and both anti-class I1 MoAbs used in these studies cross-react with human cells,13 human marrow cells became the focus of this study. We found that MoAb H81.9 specifically inhibited the growth of human high Antibodies were purified from ascites by either affinity chromatography on a Staphylococcus aureus protein A Sepharose column or by high performance liquid chromatography (HPLC) using an ABX column (IgGs) or partially purified by boric acid precipitation (IgMs) (J.T. Baker, Inc, Phillipsburg, NJ).
MATERIALS AND METHODS

Human
Lowdensity human marrow cells were washed and resuspended in phosphate-buffered saline (PBS) containing 2% FCS at 107/mL. For single-color immunofluorescence, cells were then incubated with the primary antibody for 30 minutes at 4°C and subsequently with fluorescein isothiocyanate (F1TC)-conjugated F (ab')z fragments of goat antimouse Igs (Tago, Burlingame, CA). In the control experiments, cells were incubated in MoAb H12C12 and 31.A as irrelevant IgM and IgG controls, respectively. Flow sorting was performed on a FACSII flow cytometer (Becton Dickinson, Palo Alto, CA). For two-color immunofluorescence, isotypespecific second-stage fluorescinated reagents were used. IgM MoAbs were detected with phycoerythrin (PE)-conjugated goat antibody to mouse IgM (Tago). IgG MoAbs were detected with FITC-conjugated goat antibodies to mouse IgG (Tago), respectively. Cells were analyzed as described above, except that cells in the neutrophil region of the two-dimensional scatter plot, which were uniformly negative with both anti-class I1 MoAbs and CD34 MoAbs, were excluded from the analysis. The positive fluorescent gate cutoff was set at 100% of the background population. Flow cytometric analysis was performed using ReProMan software (Becton Dickinson).
Hematopoietic growth factors (HGFs). Recombinant human stem cell factor (SCF), interleukin-3 (IL-3), IL-1, granulocytemacrophage colony-stimulating factor (GM-CSF) (kindly provided by Dr Kris Zsebo, Amgen Corp, Thousand Oaks, CA), and Marrow cells.
MoAbs.
Cell staining and fluorescence-activated cell sorting (FA CS).
erythropoietin (EPO) (purchased from Amgen Corp) were produced in Escherichia coli. They were used as purified material at 100 ng/mL (SCF), 20 ng/mL (IL-1 GM-CSF), 50 ng/mL (IL-3), and 2 U/mL (EPO).
The reactivity of hematopoietic progenitors with anti-class I1 MoAbs was assessed by a complement cytotoxicity assay as described elsewherc6 Briefly, low density marrow cells were incubated with a saturating concentration of antibody at 4°C for 60 minutes. After two washes in PBS supplemented with 2% FCS, marrow cells were incubated with rabbit complement (C') (Pelfreeze, Rogers, AR) at 37°C for 60 minutes. Control cells were incubated with medium alone or medium and C'. Preliminary experiments with graded concentrations of C' and MoAb were performed to establish the optimal concentrations of both reagents. For these experiments a single batch of rabbit C' was selected. Controls showed that this batch by itself was not cytotoxic for human marrow cells. Furthermore, control cultures showed that at the end of the cytotoxicity assay, marrow cells incubated with anti-class I1 MoAbs and C' were completely depleted of MHC class I1 positive cells, whereas MHC class I1 negative cells were unaffected by this procedure. Marrow cells were then plated in clonal agar assays to measure the specific effect of the lysis.
A double-layer nutrient agar culture consisting of a 1-mL under-layer of 0.5% agar plus hematopoietic growth factors and MoAbs and a 0.5-mL overlay of 0.3% agar plus target cells in 35" Petri dishes was used essentially as previously described.I7 However, in these experiments the X2 strength medium consisted of the following: 1 part X3 a-minimal essential medium (GIBCO), 1 part FCS (Hyclone), 0.2% bovine serum album (Sigma, St Louis, MO; no. A-7906). This X2 medium was mixed 1:l with either 1% or 0.66% DIFCO (Detroit, MI) noble agar in water. Cultures were incubated at 37°C in a 5% 0 2 , 5 % COz, 90% NZ gas mixture, as previously described for optimal colony formation.'* CFU-GM and BFU-e were scored at 14 days using an inverted microscope while HPP-CFC-type colonies were enumerated at 21 days and identified as macroscopic colonies (> 50,000 cells/colony) with diameters greater than 1.0 mm with a dense cell center using a dissecting microscope at x 10 magnification. The morphology of cells in the colonies was determined by cytospin preparations of individually picked colonies stained with benzidine and counterstained with Wright-Giemsa (Sigma).
Cytolytic treatment ofbone marrow.
Clonal agar assay for human marrow. or B1F6 + C', respectively, was: BFU-e 7% ? 2% a n d 24% t 5%, CFU-GM was 7% f 1% a n d 28% f 2%, a n d HPP-CFC, 0% and 0%. These findings indicate that the epitopes recognized by both our investigated anti-class I1 MoAbs are expressed on both early (HPP-CFC, BFU-e) and late (CFU-GM) hematopoietic progenitor cells. The C'-mediated cytotoxicity of CFU-GM and BFU-e mediated by MoAb B1F6 was greater than with MoAb H81.9. Cytotoxicity of HPP-CFC appeared complete using either
RESULTS
MHC class 11 expression
MoAb . BFU-e colony growth was markedly reduced to a mean of 45% (range 24% to 66%) of control cultures (Fig 1) . The isotype matched anti-class I1 MoAb B1F6 also had little effect on CFU-GM colony growth, and also, contrary to MoAb H81.9, did not inhibit BFU-e colony formation (Fig  1) . However, most striking was the inhibitory effect of MoAb H81.9 on the development of the characteristic macroscopic colonies of HPP-CFC and greater than 1.0 mm CFC. In contrast, HPP-CFC development was not inhibited in the presence of MoAb B1F6 or the irrelevant IgG control antibody (Fig 1) .
Effect
The observed inhibition of BFU-e and HPP-CFC formation grown from unfractionated marrow in the presence of MoAb H81.9 was antibody-concentration dependent. Maximal inhibitory effects on BFU-e growth were observed at concentrations greater than 25 pg/mL MoAb H81.9, with significant inhibition of colony growth still evident at antibody concentrations as low as 0.4 pg/mL (Fig 2) . The dose-response curve for MoAb H81.9 inhibition of HPP-CFC development was similar to that for BFU-e, with a substantial inhibition evident at 1 pg/mL (41%) that eventually reached 5% growth compared with controls at 50 pg/mL (Fig 2) .
Effects of continuous exposure to anti-class IZMoAbs on the growth of human unfractionated hematopoietic cells grown in the presence or absence of SCF. In agar cultures of human marrow cells, human SCF synergizes with other hematopoietic growth factors resulting in increased progenitor cell growth of the myeloid and erythroid 1ir1eages.l~ In the present study, CFU-GM colony formation was increased up to 1.5-fold in the presence of SCF. More strikingly, BFU-e growth was increased 7-to 10-fold in cultures containing SCF (Table 2) . To investigate whether anti-class I1 MoAbs interfere with stimulatory signals for proliferation of early hematopoietic progenitor cells, agar assays containing hematopoietic growth factors in optimal concentrations with or without stem cell factor were performed (Table 2 ).*O In the absence of SCF, neither CFU-GM nor BFU-e colony formation was affected by either anti-class I1 MoAb. In contrast, a 55% inhibition of BFU-e growth was observed in cultures exposed to SCF plus MoAb H81.9. No inhibition of growth was observed in control cultures (Fig 1) . These findings indicate that MoAb H81.9 selectively inhibited BFU-e that depend on SCF for proliferation. The effect of MoAb H81.9 on human HPP-CFC that can develop in the absence of SCF could not be determined in these experiuse only. Effect of continuous exposure to anti-class ZZ MoAbs on the growth of enriched human marrow progenitor cells plated at low cell densities. To further clarify the cell population involved in the inhibitory effects of MoAb H81.9, enriched progenitor cells were cultured at low cell densities. CD34-positive marrow cells were flow sorted and either plated at 3,000 cells/plate or set up as a cell dose response in the same experiment (375 to 3,000 cells/plate) in the presence of the above-described hematopoietic growth factors, including SCF and MoAbs. In striking contrast to the results described above using unfractionated marrow plated at relatively high cell densities, no significant H81.9 MoAbmediated growth inhibition of any progenitors was seen in low cell density, CD34-positive cultures. The results of a representative cell dose experiment are shown in Fig 3. A reanalysis of the sorted cells used in this experiment indicated that 94.5% were CD34+. When this CD34+-enriched cell population was plated at doubling cell concentrations in the presence of control MoAb, the number of hematopoietic progenitors that formed colonies was essentially linear for both BFU-e and HPP-CFC, indicating an apparent lack of cell-cell modulating effects (Fig 3) . In contrast, the number of CFU-GM that formed colonies was not linear using the cell concentrations tested, regardless of the presence or absence of MoAb. That is, the frequency of CFU-GMvaried from 125 2 per 1,000 CD34+ cells (n = 24) when plated at the lowest cell density and then progressively decreased to 100 8 (n = E ) , 63 f 7 (n = 6), and finally 42 +-3 (n = 3) CFU-GM per 1,000 cells as the cell density was increased by twofold increments. Thus, a cellular derived inhibitory activity in control MoAb cultures that was active on CFU-GM, but not HPP-CFC or BFU-e, could be detected. Unexpectedly, the addition of MoAb H81.9 did not result in any further significant inhibition of progenitors; however, consistently fewer HPP-CFC formed in low cell concentration cultures that contained MoAb H81.9 (Fig 3) . However, these slight differences in HPP-CFC growth were not statistically significant. Thus, MoAb H81.9 was markedly inhibitory to HPP-CFC and BFU-e only when grown in the presence of unfractionated marrow cells cultured at relatively high density (40,000 cells/plate).
DISCUSSION
Major histocompatibility complex class I1 antigens are known to be involved in cell-cell interactions in hematopoiesis and are differentially expressed on human hematopoi- etic progenitor and other marrow cell^.^-^ Certain class I1 epitopes appear to be of functional importance in the regulation of early hematopoiesis6 as indicated by studies of autologous transplants in otherwise lethally irradiated dogs in which administration of the HLA-DR-specific MoAb H81.9 lead to late graft failure. Interference with hematopoietic engraftment was seen when MoAb H81.9 was injected during the first 4 days after TBI and marrow infusion. MoAb H81.9 recognizes an epitope formed by the a and @ subunits of HLA-DR. In contrast, MoAb BlF6, directed against an epitope on the @ subunit of the HLA-DR and DP MHC class I1 molecules, did not affect hematopoietic repopulation in this modeL6
In the present study, we first show that both MoAb H81.9 and B1F6 specifically mediate C' lysis of the majority of CFU-GM and BFU-e and apparently all HPP-CFC ( Table  1 ). The detection of human HPP-CFC was based on identification of macroscopic colonies (> 1.0 mm diameter) with a dense cell center containing greater than 50,000 cells. Recent studies in both humans and baboons have shown that HPP-CFC are CD34+ HLA-DR+ relatively noncycling (5-fluorouracil resistant), primitive (retain low levels of rhodamine 123) progenitor cells that, unlike more differentiated progenitors, require the presence of multiple hematopoietic growth factors to proliferate12 (and S.H.B., unpublished observations, January 1992). Thus, human HPP-CFC are phenotypically similar to the well-characterized murine HPP-CFC,22,23 subpopulations of which have been shown to be identical to or cofractionate with colony-forming unitsspleen day 8 and day 12 as well as &e more immature long-term repopulating cells. 24 In experiments using unfractionated marrow, colonyforming cells responsive to a single hematopoietic growth factor, eg, CFU-GM, were not inhibited in the presence of either anti-class I1 MoAb. In contrast, colony-forming cells that required multiple hematopoietic growth factors for growth, such as HPP-CFC and BFU-e, were markedly inhibited by MoAb H81.9, but not by the isotype-matched MoAb B1F6 or the irrelevant control MoAb. Interestingly, only SCF-dependent BFU-e growth was inhibited by MoAb H81.9 using unfractionated marrow, while BFU-e that were able to proliferate in the absence of SCF were not affected by the anti-class I1 MoAb. These findings suggest that MoAb H81.9 specifically inhibits more primitive progenitors, leaving more differentiated progenitors unaffected when unfractionated cells are plated at relatively high cell densities.
To further elucidate the mechanism of the effect of MoAb H81.9 on primitive progenitor cells, low-density cell dose-response experiments were performed. The marked inhibitory effects of MoAb H81.9 on both HPP-CFC and BFU-e colony formation observed with unfractionated marrow were not seen using CD34-positive cells cultured at low cell densities (375 to 3,000 cells/35-mm plate), although a consistent slight, but not statistically significant, inhibition of HPP-CFC growth occurred at all the lower cell densities tested. This is most consistent with the possibility that the inhibitory effect of MoAb H81.9 is predominantly mediated indirectly through an HLA-DR-positive cell population.
Both positive and negative regulators influence hematopoiesis and the net production of mature hematopoietic cells appears to reflect the balance between the levels and activity of inhibitors and stimulator^.^^ The target cell populations for these mediators appears to be specific for various subpopulations of progenitors ranging from relatively mature (eg, CFU-GM) to relatively "primitive" (eg, CFU-S, CFU-MIX, HPP-CFC). Whereas certain hematopoietic growth factors have positive effects on these different classes of progenitor^,^^-^^ transforming growth factor @ (TGF@),30-32 macrophage inflammatory protein-la (MIP1a),33,34 tumor necrosis factor a ( T N F U ) ,~~ and interfer0ns36,37 have been shown to have inhibitory (as well as stimulatory) effects. The specific inhibitory effects of MoAb H81.9 on early hematopoietic progenitor cells appear to be similar to that described for certain isoforms of TGF@ that are known to inhibit SCF-dependent colony formation of both murine and human progenitor^.^^ However, a major difference between the inhibition mediated by MoAb H81.9 and TGFp is that the TGFp effect appears to be reversible use only. An alternative explanation for the observations reported in this study is that apparent inhibition may in fact be a rapid differentiation event. The failure of HPP-CFC, for example, to develop its full proliferative potential in vitro could be caused by the HPP-CFC rapidly differentiating to, eg, the low proliferative potential CFU-GM state unusually fast. Highly enriched murine repopulating cells (ie, CFU-S) have recently been shown to differentiate rapidly in vitro under the influence of specific hematopoietic growth factors. This mechanism correlates with the in vivo observations that the effect of H81.9 on LTRC appears to be irreversible.6 Most physiologic inhibitors are reversible, and thus MoAb H81.9 may be inducing the release of potent differentiative mediators.
